- Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts — Active Not Recruiting • Phase III • NCT05369975.
- Imlifidase allows highly sensitized kidney transplant patients with positive crossmatch to receive transplants safely, with good one-year graft survival.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior to desensitized with imlifidase and subsequent kidney transplantation. Two non-comparative reference cohorts are included to assess the impact of differences in post-transplantation management and outcome in less sensitized patients. Conditions: Kidney Transplantation in Highly Sensitized Patients Interventions: Imlifidase, Normal Transplantation Routine Lead Sponsor: Hansa Biopharma AB Planned Enrollment: 225 participants